Secondary prevention of coronary artery disease in contemporary clinical practice

Cardiology Journal

Volumn 22, Issue 2, 2015, Pages 219-226

  Jankowski, Piotr ^a   Czarnecka, Danuta ^a   Wolfshaut Wolak, Renata ^a   Łysek, Radosław ^a   Łukaszewska, Anna ^a   Bogacki, Piotr ^b   Grodecki, Janusz ^c   Mirek Bryniarska, Ewa ^d   Nessler, Jadwiga ^a   Podolec, Piotr ^a   Kawecka Jaszcz, Kalina ^a   Pająk, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Ludwik Rydygier District Hospital   (Poland)

^c Gabriel Narutowicz Hospital   (Poland)

^d Jozef Dietl Hospital   (Poland)

Author keywords

Coronary artery disease; Hypercholesterolemia; Hypertension; Risk factors; Secondary prevention; Smoking

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SARTAN DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; SECONDARY PREVENTION; AGED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; FEMALE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; POLAND; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; STANDARDS; TREATMENT OUTCOME; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DRUG PRESCRIPTIONS; FEMALE; GUIDELINE ADHERENCE; HOSPITALIZATION; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL REVASCULARIZATION; PATIENT COMPLIANCE; PLATELET AGGREGATION INHIBITORS; POLAND; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84928621407     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.a2014.0066     Document Type: Article

References (19)

1. WHO, World Health Organization. The World Health Report. WHO, Geneva 2008. http://www.who.int/whr/2008/whr08_en.pdf.
2. World Health Organization Regional Office for Europe (HFA-DB), European health for all database. April 2014.
3. Rządowa Rada Ludnościowa. Sytuacja Demograficzna Polski. Raport 2011–2012. Warszawa 2012.
4. De Bacquer D, Dallongeville J, Kotseva K et al. Residual risk of cardiovascular mortality in patients with coronary heart disease: The EUROASPIRE Risk Categories. Int J Cardiol, 2013; 168: 910–914.
5. Simpson CR, Buckley BS, McLernon DJ, Sheikh A, Murphy A, Hannaford PC. Five-year prognosis in an incident cohort of people presenting with acute myocardial infarction. PLoS One, 2011; 6: e26573.
6. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J, 2012; 33: 1635–1701.
7. Kawecka-Jaszcz K, Pająk A, Jankowski P. Krakow Program for Secondary Prevention of Ischaemic Heart Disease. Part I. Genesis and objectives. Przegl Lek, 2001; 58: 953–955.
8. Jankowski P, Kawecka-Jaszcz K, Pająk A et al. Cracovian program for secondary prevention of ischemic heart disease. Secondary prevention of ischemic heart disease after discharge in 1997–1998 and 1999–2000. Przegl Lek, 2003; 60: 142–146.
9. Kotseva K, Wood D, De Backer GD, De Bacquer D, Pyörälä K, Keil U; The EUROASPIRE Study Group. EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. EJCPR, 2009; 16: 121–137.
10. Pajak A, Jankowski P, Kawecka-Jaszcz K et al. Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997–2007. Comparison of Cracovian Pro gram for Secondary Prevention of Ischaemic Heart Disease and Polish parts of EUROASPIRE II and EUROASPIRE III surveys. Kardiol Pol, 2009; 67: 1353–1359.
11. Jankowski P, Czarnecka D, Łysek R et al. Secondary prevention in patients after hospitalization due to coronary artery disease: What has changed since 2006? Kardiol Pol, 2014; 72: 355–362.
12. Poloński L, Gasior M, Gierlotka M et al. Polish Registry of Acute. Coronary Syndromes (PL-ACS). Characteristics, treatments and outcomes of patients with acute coronary syndromes in Poland. Kardiol Pol, 2007; 65: 861–872.
13. Grajek S, Lesiak M, Araszkiewicz A et al. Short- and longterm mortality in patients with ST-elevation myocardial infarction treated with different therapeutic strategies. Results from WIelkopolska REgional 2002 Registry (WIRE Registry). Kardiol Pol, 2008; 66:154–163.
14. Yusuf S, Islam S, Chow CK et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet, 2011; 378: 1231–1243.
15. Jankowski P, Czarnecka D, Wolfshaut-Wolak R et al. Age, sex, and secondary prevention of ischaemic heart disease in everyday practice. Kardiol Pol, 2013; 71: 1251–1259.
16. Heran BS, Chen JM, Ebrahim S et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev, 2011; 7: CD001800.
17. Brown JP, Clark AM, Dalal H, Welch K, Taylor RS. Patient education in the management of coronary heart disease. Cochrane Database Syst Rev, 2011; 12: CD008895.
18. Wood DA, Kotseva K, Connolly S et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: A paired, cluster-randomised controlled trial. Lancet, 2008; 371: 1999–2012.
19. Jankowski P, Niewada M, Bochenek A et al. Optimal model of comprehensive rehabilitation and secondary prevention. Kardiol Pol, 2013; 71: 995–1003.